As an easily calculated composite indicator, AIP-BMI offers strong clinical interpretability and can directly inform risk stratification, enabling the identification of ischemic stroke patients presenting with both dyslipidemia and overweight or obese individuals who may represent a particularly high-risk subgroup for PSCI. The gene discussed is AIP; the disease is metabolic syndrome.